tiprankstipranks
Advertisement
Advertisement

PCRX Stock Latest News

Pacira Earnings Call Highlights Growth, Pipeline Momentum
Company AnnouncementsPacira Earnings Call Highlights Growth, Pipeline Momentum
1d ago
PCRX
Pacira price target raised to $32 from $30 at Needham
PremiumThe Fly
Pacira price target raised to $32 from $30 at Needham
2d ago
PCRX
AI Models Turn More Positive on Pacira Pharmaceuticals as Cash Flow and Balance Sheet Strength Offset Valuation Concerns
PremiumAI Analyst Ratings
AI Models Turn More Positive on Pacira Pharmaceuticals as Cash Flow and Balance Sheet Strength Offset Valuation Concerns
2d ago
PCRX
Pacira reports Q1 EPS 60c, consensus 56c
PremiumThe Fly
Pacira reports Q1 EPS 60c, consensus 56c
2d ago
PCRX
Pacira backs FY26 revenue view $745M-$770M, consensus $760.65M
PremiumThe Fly
Pacira backs FY26 revenue view $745M-$770M, consensus $760.65M
2d ago
PCRX
PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsPCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5d ago
PCRX
Exparel’s Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences
Premium
Ratings
Exparel’s Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences
20d ago
PCRX
Pacira real-world data clearer in hip arthroplasty, says H.C. Wainwright
Premium
The Fly
Pacira real-world data clearer in hip arthroplasty, says H.C. Wainwright
20d ago
PCRX
Pacira presents data showing lower healthcare costs for Exparel
PremiumThe Fly
Pacira presents data showing lower healthcare costs for Exparel
20d ago
PCRX
Pacira price target lowered to $25 from $27 at Barclays
PremiumThe Fly
Pacira price target lowered to $25 from $27 at Barclays
1M ago
PCRX
Doma Perpetual nominates three to Pacira board
PremiumThe Fly
Doma Perpetual nominates three to Pacira board
2M ago
PCRX
Pacira reports inducement grants under Nasdaq listing rule
PremiumThe Fly
Pacira reports inducement grants under Nasdaq listing rule
2M ago
PCRX
Pacira Earnings Call Highlights Margin Gains And Growth
PremiumCompany AnnouncementsPacira Earnings Call Highlights Margin Gains And Growth
2M ago
PCRX
Pacira presents evidence real-world evidence from IGOR
Premium
The Fly
Pacira presents evidence real-world evidence from IGOR
2M ago
PCRX
Pacira: Conservative 2026 Outlook, Margin Discipline, and NOPAIN Act Tailwinds Support Buy Rating
Premium
Ratings
Pacira: Conservative 2026 Outlook, Margin Discipline, and NOPAIN Act Tailwinds Support Buy Rating
2M ago
PCRX
Pacira reports Q4 EPS 57c, consensus 90c
PremiumThe Fly
Pacira reports Q4 EPS 57c, consensus 90c
2M ago
PCRX
Pacira sees FY26 revenue $745M-$770M, consensus $792.23M
PremiumThe Fly
Pacira sees FY26 revenue $745M-$770M, consensus $792.23M
2M ago
PCRX
PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
PCRX
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court
PremiumClass Action
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court
2M ago
PCRX
Pacira highlights new NOPAIN act survey data conducted by Voices
PremiumThe FlyPacira highlights new NOPAIN act survey data conducted by Voices
3M ago
PCRX
Pacira reports inducement grants under Nasdaq listing rule
Premium
The Fly
Pacira reports inducement grants under Nasdaq listing rule
3M ago
PCRX
Pacira BioSciences adds seasoned leader to board
Premium
Company Announcements
Pacira BioSciences adds seasoned leader to board
3M ago
8K
PCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >